EU Paediatric Rewards: More Questions Than Answers
This article was originally published in SRA
Executive Summary
Geneviève Michaux explores the complicated business of obtaining rewards available under the EU Paediatric Regulation.
You may also be interested in...
Pharma Attacked For “Playing The System” Of EU Pediatric Rewards
As a public consultation on the impact of the EU Paediatric Regulation comes to an end, the French drug bulletin Prescrire has attacked pharma firms for taking advantage of the rewards and incentives provided in the regulation and paying only lip service to the need for new medicines for children.
Lilly Can Rest Easy As Tirzepatide Scores Phase III Sleep Apnea Win
Topline results from two studies in obstructive sleep apnea among obese adults showed efficacy crossing the 50% threshold that physicians have called clinically meaningful.
China’s Public Payer Wants To Define Innovative Drugs As Those With ‘Novel Benefits’
China’s public payer perceives innovative drugs in a different way from that of the country’s top drug regulator, a former senior healthcare security official with knowledge of the matter reveals. The posture has unnerved pharma companies, which have been hit by sharp price discounts.